Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Emerging Biotech & Pharma Index: 36 More Cos.
Nov 24, 2008 01:40 AM
- Analyst Comments: Corrections Corp, Alnylam Pharma, Ryland, Eurand Pharma, HCP
Aug 11, 2008 12:23 PM
- Analyst Comments: China Eastern Airlines, Aladdin, Alnylam Pharmaceuticals, American Oriental, Arch Coal
Jul 22, 2008 08:00 AM
- Investing in microRNA - Beware of Hype, Follow The Money
Jun 04, 2008 01:24 PM
- Analyst Comments: Alpharma, Shanda, Sonic Solutions, HSBC Holdings, Ferrellgas, TriZetto, Compuware, American Axle, Alnylam
May 30, 2008 06:27 PM
- Another RNAi Drugs Deal
May 29, 2008 04:05 PM
- The Metrics of Growth in China Biopharma
May 17, 2008 05:13 PM
- Alnylam Pharma: Novartis To Buy Added 213,888 Shares
May 08, 2008 09:41 AM
- Alnylam Pharma: Novartis To Buy Added 213,888 Shares
May 08, 2008 09:41 AM
- UPDATE: GlaxoSmithKline Signs Regulus Gene Research Deal
Apr 17, 2008 10:21 AM
- Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model
Nov 30, 2008 01:11 PM
- Alnylam to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
Nov 26, 2008 04:01 PM
- Alnylam Presents Pre-clinical Data from TTR Amyloidosis Development
Program
Nov 20, 2008 08:18 AM
- IMM, Cenix, and Alnylam Discover New Targets in Malaria Infection with RNAi Technology
Nov 11, 2008 08:11 AM
- Alnylam to Webcast Presentation at the Rodman & Renshaw 10th Annual Healthcare Conference
Nov 06, 2008 04:03 PM
- Regulus Therapeutics and Collaborators Discover Role of a microRNA in Tumor Angiogenesis
Nov 06, 2008 08:15 AM
- Alnylam Pharmaceuticals Reports Third Quarter 2008 Financial Results
Nov 05, 2008 04:02 PM
- Alnylam and Collaborators Publish New Pre-clinical Research on Therapeutic Silencing of Key Gene Implicated in Parkinson's Disease
Nov 04, 2008 01:22 PM
- Alnylam and Collaborators Publish Research on a New Class of Chemically Modified RNAi Therapeutics that Target Two Distinct Cellular Mechanisms
Nov 03, 2008 08:35 AM
- Alnylam to Webcast Conference Call Discussing Third Quarter 2008 Financial Results
Oct 29, 2008 04:03 PM
- Form 4 Schmidt John A Jr For: Sep 29 (10K)
Oct 01, 2008 06:17 PM
- Form 3 Schmidt John A Jr For: Sep 29 (10K)
Oct 01, 2008 06:17 PM
- Form 4 ALNYLAM PHARMACEUTICALS, For: Aug 18 Filed by: MARAGANORE JOHN (10K)
Aug 19, 2008 04:03 PM
- Form 4 ALNYLAM PHARMACEUTICALS, For: Aug 13 Filed by: MARAGANORE JOHN (10K)
Aug 15, 2008 04:37 PM
- Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 03 Filed by: STARR KEVIN P (10K)
Jun 05, 2008 04:40 PM
- Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 03 Filed by: VINCENT JAMES L (10K)
Jun 05, 2008 04:40 PM
- Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 03 Filed by: SHARP PHILIP A (10K)
Jun 05, 2008 04:39 PM
- Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 03 Filed by: SATO VICKI L (10K)
Jun 05, 2008 04:38 PM
- Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 03 Filed by: SCHIMMEL PAUL (10K)
Jun 05, 2008 04:38 PM
- Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 03 Filed by: DZAU VICTOR J (10K)
Jun 05, 2008 04:38 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
ALNY
|
Compare to S&P
|
| YTD |
-37.31 %
|
2.71 %
|
| 4 Weeks |
-20.74 %
|
-14.33 %
|
| 12 Weeks |
-34.35 %
|
-9.01 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 77.42 %
|
|
EPS Growth in Last Year: 94.26 %
|
|
Sales Growth in Last Quarter: 7.98 %
|
|
Sales Growth in Last Quarter: 57.73 %
|
|
|
